ArticleSurgical case reports2026
A Case of Intraductal Tubulopapillary Neoplasm of the Pancreas Requiring Superior Mesenteric Vein-Portal Vein Axis Resection after Systemic Chemotherapy.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIntraductal tubulopapillary neoplasm (ITPN) is a rare intraductal pancreatic tumor, accounting for approximately 3% of all intraductal neoplasms. ITPN is characteristically paucimucinous and lacks low-grade (adenomatous) components. Since reported cases of ITPN remain limited, its prognosis, prognostic factors, and role of perioperative chemotherapy are not well defined. CASE PRESENTATION: A 64-year-old man presented with loss of appetite and abdominal pain in year X-1. Endoscopic US-guided fine-needle aspiration (EUS-FNA) was performed, and the findings showed atypical epithelial cells suspicious for adenocarcinoma. The lesion was radiologically assessed as borderline-resectable pancreatic head cancer with portal venous involvement. Curative-intent resection was attempted at the referring hospital; however, the tumor was judged intraoperatively to be locally unresectable because safe vascular dissection around the superior mesenteric vein (SMV) was difficult. Choledochojejunostomy, cholecystectomy, and gastrojejunostomy were performed for obstructive jaundice and duodenal stenosis. From October X-1, the patient received gemcitabine plus nab-paclitaxel, followed by tegafur/gimeracil/oteracil. The maximum tumor diameter decreased from 60 to 50 mm, and the imaging response to systemic chemotherapy was classified as stable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, without distant progression. In May X, the patient was referred to our department for consideration of surgical treatment. Repeat EUS-FNA strongly suggested ITPN. Subtotal stomach-preserving pancreatoduodenectomy with SMV-portal vein (PV) axis resection and reconstruction was performed using a right common femoral vein graft. Postoperative right deep femoral vein thrombosis was managed with anticoagulation. The patient was discharged on POD 16, and follow-up CT 1 year after surgery confirmed thrombus resolution. Histopathological examination confirmed invasive ITPN without lymph node metastasis or vascular invasion. The histological treatment effect was classified as grade 1a according to the Japanese classification of pancreatic carcinoma by the Japan Pancreas Society, eighth edition, and as grade I according to the Evans classification. Adjuvant chemotherapy was not administered. The patient remained disease-free 29 months after surgery.
conclusionsThis case highlights the importance of multidisciplinary re-evaluation in pancreatic tumors initially managed as pancreatic ductal adenocarcinoma, particularly when an unusual histology such as ITPN is suspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.